318 related articles for article (PubMed ID: 19527482)
1. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
[TBL] [Abstract][Full Text] [Related]
2. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Nuotio-Antar AM; Hachey DL; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
[TBL] [Abstract][Full Text] [Related]
3. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
[TBL] [Abstract][Full Text] [Related]
4. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
6. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344).
Park JS; Rhee SD; Kang NS; Jung WH; Kim HY; Kim JH; Kang SK; Cheon HG; Ahn JH; Kim KY
Biochem Pharmacol; 2011 Apr; 81(8):1028-35. PubMed ID: 21315688
[TBL] [Abstract][Full Text] [Related]
7. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
Véniant MM; Hale C; Komorowski R; Chen MM; St Jean DJ; Fotsch C; Wang M
Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
[TBL] [Abstract][Full Text] [Related]
9. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
10. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
14. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
15. 11β-HSD1 inhibition reduces atherosclerosis in mice by altering proinflammatory gene expression in the vasculature.
Luo MJ; Thieringer R; Springer MS; Wright SD; Hermanowski-Vosatka A; Plump A; Balkovec JM; Cheng K; Ding GJ; Kawka DW; Koo GC; Grand CB; Luo Q; Maletic MM; Malkowitz L; Shah K; Singer I; Waddell ST; Wu KK; Yuan J; Zhu J; Stepaniants S; Yang X; Lum PY; Wang IM
Physiol Genomics; 2013 Jan; 45(1):47-57. PubMed ID: 23170035
[TBL] [Abstract][Full Text] [Related]
16. Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Nakano S; Inada Y; Masuzaki H; Tanaka T; Yasue S; Ishii T; Arai N; Ebihara K; Hosoda K; Maruyama K; Yamazaki Y; Shibata N; Nakao K
Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E1213-22. PubMed ID: 17190905
[TBL] [Abstract][Full Text] [Related]
17. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
Apostolova G; Schweizer RA; Balazs Z; Kostadinova RM; Odermatt A
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E957-64. PubMed ID: 15613680
[TBL] [Abstract][Full Text] [Related]
18. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
19. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.
Paulsen SK; Nielsen MP; Richelsen B; Bruun JM; Flyvbjerg A; Pedersen SB
Obesity (Silver Spring); 2008 Apr; 16(4):731-5. PubMed ID: 18379559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]